By Rupert Hargreaves GSK announced today that it has taken the first steps to appeal the Delaware Superior Court’s recent so-called Daubert ruling over its allegedly carcinogenic heartburn treatment Zantac. The ruling, handed down two weeks ago by Judge Vivian Medinilla, stated that scientific evidence presented by lawyers in more than 70,000 cases was admissible, an outcome GSK and its peers had been seeking to block. The ruling left the company open to US jury trials regarding liability and potentially enormous settlement costs. In 2022, Morgan Stanley analysts estimated the industry’s poten…